Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexandre Prat

Showing results (201-210 of 268) with videos related to

Pageof 27
Sort By:
Journal of Neuroscience Research|March 23, 2026
Age and Maturation Stage Linked Consequences of Fibrinogen on Human OligodendrogliaGabriela J Blaszczyk, Chao Weng, Abdulshakour Mohammadnia, et al.
Nature|June 21, 2024
Author Correction: Disease-associated astrocyte epigenetic memory promotes CNS pathologyHong-Gyun Lee, Joseph M Rone, Zhaorong Li, et al.
Science Translational Medicine|January 5, 2022
DICAM promotes T<sub>H</sub>17 lymphocyte trafficking across the blood-brain barrier during autoimmune neuroinflammationMarc Charabati, Camille Grasmuck, Soufiane Ghannam, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 19, 2022
Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosisChao Zhu, Zhen Zhou, Izanne Roos, et al.
JAMA Neurology|August 8, 2018
Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple SclerosisJordana Hughes, Vilija Jokubaitis, Alessandra Lugaresi, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 30, 2022
Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national registrySifat Sharmin, Charles B Malpas, Izanne Roos, et al.
Cell Reports|June 22, 2022
Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimenManon Nayrac, Mathieu Dubé, Gérémy Sannier, et al.
Annals of Neurology|May 5, 2016
Predictors of long-term disability accrual in relapse-onset multiple sclerosisVilija G Jokubaitis, Tim Spelman, Tomas Kalincik, et al.
CNS Drugs|February 14, 2025
Treatment De-escalation in Relapsing-Remitting Multiple Sclerosis: An Observational StudyJannis Müller, Sifat Sharmin, Johannes Lorscheider, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 30, 2016
Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosisNathaniel Lizak, Alessandra Lugaresi, Raed Alroughani, et al.
Pageof 27

Showing results (201-210 of 268) with videos related to

Sort By:
Pageof 27
Journal of Neuroscience Research|March 23, 2026
Age and Maturation Stage Linked Consequences of Fibrinogen on Human OligodendrogliaGabriela J Blaszczyk, Chao Weng, Abdulshakour Mohammadnia, et al.
Nature|June 21, 2024
Author Correction: Disease-associated astrocyte epigenetic memory promotes CNS pathologyHong-Gyun Lee, Joseph M Rone, Zhaorong Li, et al.
Science Translational Medicine|January 5, 2022
DICAM promotes T<sub>H</sub>17 lymphocyte trafficking across the blood-brain barrier during autoimmune neuroinflammationMarc Charabati, Camille Grasmuck, Soufiane Ghannam, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 19, 2022
Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosisChao Zhu, Zhen Zhou, Izanne Roos, et al.
JAMA Neurology|August 8, 2018
Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple SclerosisJordana Hughes, Vilija Jokubaitis, Alessandra Lugaresi, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 30, 2022
Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national registrySifat Sharmin, Charles B Malpas, Izanne Roos, et al.
Cell Reports|June 22, 2022
Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimenManon Nayrac, Mathieu Dubé, Gérémy Sannier, et al.
Annals of Neurology|May 5, 2016
Predictors of long-term disability accrual in relapse-onset multiple sclerosisVilija G Jokubaitis, Tim Spelman, Tomas Kalincik, et al.
CNS Drugs|February 14, 2025
Treatment De-escalation in Relapsing-Remitting Multiple Sclerosis: An Observational StudyJannis Müller, Sifat Sharmin, Johannes Lorscheider, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 30, 2016
Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosisNathaniel Lizak, Alessandra Lugaresi, Raed Alroughani, et al.
Pageof 27